Wednesday, June 10, 2026

Intelligence · Patents

Patents expiring in 2033

Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.

Patents
1,330

Quick answer

1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8399219

    Protease activatable interferon alpha proprotein

    CytomX Therapeutics, Inc. · Granted Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 8399025

    Polyamine modified particles

    The Board of Regents of the University of Texas System · Granted Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 8399412

    Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 8399512

    Biocompatible biodegradable fumagillin analog conjugates

    Mersana Therapeutics, Inc. · Granted Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 8399428

    Nucleosides with antiviral and anticancer activity

    Regents of the University of Minnesota · Granted Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 8399018

    Controlled release ion channel modulator compositions and methods for the treatment of otic disorders

    The Regents of the University of California · Granted Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 8404817

    Humanized anti-prostate stem cell antigen monoclonal antibody

    The Regents of the University of California · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 8404222

    Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution

    Nektar Therapeutics · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8404635

    Orally administered peptides synergize statin activity

    The Regents of the University of California · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8404264

    Functionalizing implantable devices with a poly (diol citrate) polymer

    Northwestern University · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 8404643

    Metastin derivatives and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 8404862

    Ligand-conjugated monomers

    Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 8404852

    Gyrase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 8404869

    Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome

    MAZENCE INC. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 8404732

    Methods of treating ulcerative colitis

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 8404818

    Monoclonal antibodies against orthopoxviruses

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 8404849

    Processes for producing modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 8404806

    Isolated BRCA1 peptides and method of use

    The Regents of the University of California · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 8404288

    Microbially-stable vitamin E solutions

    Sunny Delight Beverage Company · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 8404810

    Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma

    Five Prime Therapeutics, Inc. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  21. US 8404711

    5-HT4 receptor agonist compounds for treatment of cognitive disorders

    Theravance, Inc. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  22. US 8404638

    Dimer VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  23. US 8404650

    Methods of treating cancer with doxazolidine and prodrugs thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  24. US 8404632

    Compositions and methods for the delivery of nitric oxide

    The Regents of the University of California · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  25. US 8404631

    Compositions and methods for the delivery of oxygen

    The Regents of the University of California · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  26. US 8404244

    Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  27. US 8404300

    Drug releasing coatings for medical devices

    Lutonix, Inc. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  28. US 8403844

    Methods for interventions

    BioMarker Pharmaceuticals, Inc. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  29. US 8403876

    Indwelling heat exchange catheter and method of using same

    The Regents of the University of California · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  30. US 8403910

    Drug releasing coatings for medical devices

    Lutonix, Inc. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  31. CA 2851492

    COMPOSITIONS OPHTALMIQUES EN GEL

    BAUSCH & LOMB [US] · Granted Thu Mar 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  32. CA 2849366

    COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER

    ALLERGEN INC [US] · Granted Thu Mar 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  33. US 8410267

    Regioselective reduction of fused pyrrolocarbazoles-5,7-diones

    Teva Sante · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  34. US 8410266

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  35. US 8410292

    Epoxy-guaiane derivatives and treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  36. US 8409126

    Selective cytopheresis devices and related methods thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  37. US 8410288

    Polymorphs of Saxagliptin hydrochloride and processes for preparing them

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  38. US 8410169

    Compounds and methods for delivery of prostacyclin analogs

    United Therapeutics Corporation · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  39. US 8410140

    Anesthetic methods and compositions

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  40. US 8410097

    Heteropyrrole analogs acting on cannabinoid receptors

    UNIVERSITY OF CONNECTICUT · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  41. US 8410132

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  42. US 8410133

    Aminopyridines useful as inhibitors of protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  43. US 8410121

    Methods of treating pulmonary hypertension

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  44. US 8410093

    Cycloalkyl substituted pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  45. US 8410078

    Composition and methods to treat cardiac diseases

    UNIVERSITY OF CONNECTICUT · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  46. US 8410081

    Treatment of cystic fibrosis

    ACADEMISCH MEDISCH CENTRUM · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  47. US 8410089

    Fused heterocyclic ring compound

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  48. US 8410063

    N-acetyl mannosamine as a therapeutic agent

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2033?

1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.